ALK and non-small cell lung carcinoma: Tyrosine kinase inhibitors targeting ALK structural aberrations (ALK-TKIs) have emerged as a cornerstone in the treatment of ALK-positive malignancies, particularly non-small cell lung cancer [8], evolving from first-generation Crizotinib to third-generation Lorlatinib [9,10,11,12].